Immune checkpoint inhibitors in chronic hepatitis B: therapy or high-risk factor for reactivation?

Hepatol Int. 2022 Apr;16(2):480-481. doi: 10.1007/s12072-022-10317-8. Epub 2022 Mar 24.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Hepatitis B Surface Antigens
  • Hepatitis B virus / genetics
  • Hepatitis B* / drug therapy
  • Hepatitis B, Chronic* / drug therapy
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Risk Factors
  • Virus Activation

Substances

  • Antiviral Agents
  • Hepatitis B Surface Antigens
  • Immune Checkpoint Inhibitors